COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS BY GENES THERAPY.

摘要

THE INVENTION REFERS TO PROCEDURES OF GENETIC THERAPY TO INHIBIT THE ANGIOGENESIS ASSOCIATED WITH THE GROWTH OF SOLID TUMORS, TUMOR METASTASIS, INFLAMMATION, PSORIASIS, REUMATOID ARTHRITIS, HEMANGIOMAS, RETINOPHYRIAGRAPHY LABEL. A METHODOLOGY OF GENETIC THERAPY IS PRESENTED TO INHIBIT PRIMARY TUMOR GROWTH AND METASTASIS THROUGH GENETIC TRANSFER OF A NUCLEOTIDE SEQUENCE CODIFYING A SOLUBLE FORM OF THE VEGF THYROSINE KINASE RECEPTOR TO A HOST. THE TRANSFERRED NUCLEOTIDE SEQUENCE TRANSCRIBES AN ARNM AND A SOLUBLE RECEIVING PROTEIN THAT JOINS A VEGF IN EXTRACELLULAR REGIONS ADJACING THE PRIMARY TUMOR AND MUSCLE ENDOTELIAL CELLS. THE FORMATION OF AN SVEGFR / VEGF COMPLEX WILL AVOID THE VEGF UNION WITH THE KDR AND FLT-1 TIROSINE KINASE RECIPIENTS, ANTAGONIZING THE TRANSDUCTION OF THE NORMAL INTRACELLULAR SIGNALS ASSOCIATED WITH THE TOTORIAL ANGULGENESIS VOTED BY THE CELL ENDOTEL. IN ADDITION, THE EXPRESSION OF A SOLUBLE RECEIVER THYROSINE KINASE CAN ALSO PROVIDE A THERAPEUTIC EFFECT BY JOINING WELL WITH OR BEN WITHOUT VEGFS TO FORM NON-FUNCTIONAL HETERODYMERS WITH THE LIGITUDE TIGOSTITE KIND, RECEIVER FOR THE LIGITUDE, INHIBIT THE MITOGENIC AND ANGIOGENIC ACTIVITIES OF VEGF.